STAT6 Opportunity to Serve Millions of Patients with Type 2
Inflammation                              DERMATOLOGY              PATIENTS1


                                                       AD           43M

      >140M                 Systemic Advanced
                                                       CSU          4.4M

                              Therapies: 1%
                                                       PN           305K
                                                       BP           166K
                                                GASTROENTEROLOGY
                                 >$20B Market
                                                       EoE          1.6M
       TOTAL POTENTIAL                          RESPIRATORY
       PATIENT IMPACT1
                                                      Asthma        55M
   An oral STAT6 degrader has the
   potential to transform the treatment               COPD          34M
   paradigm for Type 2 diseases and tap
   into large underserved markets                    CRSwNP         2.8M


                                                                               15
